Who is sponsoring NCT04439162?

NCT04439162 is sponsored by Assiut University.

What drugs are being tested in NCT04439162?

Interventions in NCT04439162: retrograde cardioplegia protection.

What condition does NCT04439162 study?

NCT04439162 studies Coronary Artery Disease Left Main.

Is NCT04439162 still recruiting?

NCT04439162 is currently status unknown. Last updated 19 June 2020.

Last reviewed 2020-06-19 · How we verify

NCT04439162

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antegrade and Retrograde Versurs Antegrade Cardioplegia in Complex Coronary Artery Bypass Surgeries

Status unknown NA Last updated 19 June 2020

What this trial tests

NA trial testing retrograde cardioplegia protection in Coronary Artery Disease Left Main in 100 participants. Status unknown.

Timeline

1 July 2020

Primary endpoint
1 June 2021

1 April 2022

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	100
Start date	1 July 2020
Primary completion	1 June 2021
Estimated completion	1 April 2022

Drugs / interventions tested

retrograde cardioplegia protection

Conditions studied

Coronary Artery Disease Left Main — all drugs for Coronary Artery Disease Left Main →

Sponsor

Assiut University

Who can join

Adults 18 to 60, any sex, with Coronary Artery Disease Left Main. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

During coronary artery bypass surgery, myocardial protection, especially of the right ventricle, may be inadequate in the presence of severe coronary lesions that obstruct the antegrade delivery of cold cardioplegia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04439162 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 19 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04439162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing